INCR — InterCure Ltd.

InterCure Q4 2022 Earnings Call Summary

1. Key Financial Results and Metrics

• Full Year Revenue: Approximately $150 million, a 77% increase from $85 million in 2021.
• Q4 Revenue: $41 million, up 30% year-over-year and 6% sequentially from Q3 2022.
• Adjusted EBITDA: $32 million for the full year, representing 22% of revenue, compared to $22 million in 2021.
• Gross Profit: Over $60 million for the year, a gross margin of 41%, down from 44% in 2021.
• Net Profit: Just under $70 million, with cash flow from operations of $20 million.
• Cash Position: Ended the year with $95 million in cash.

2. Strategic Updates and Business Highlights

• InterCure is positioned as the largest and fastest-growing cannabis company outside North America, focusing on profitable growth.
• The company expanded its pharmacy chain from 3 to 28 locations, with 20 actively dispensing medical cannabis.
• Significant investments in cultivation and production facilities, including partnerships with Organigram and Binske to enhance product offerings.
• Successful export of products to EU markets, preparing for commercial launches in Germany and the UK.
• The company is focused on scaling operations and expanding its international supply chain.

3. Forward Guidance and Outlook

• Anticipation of a prescription reform in Israel that could increase market demand by 70%, from 49 tons in 2022 to 85 tons in 2023.
• Continued focus on executing its growth strategy while navigating regulatory challenges.
• Expectation of reduced capital expenditures in 2023, projected to be at least 50% lower than 2022.
• Plans to expand the pharmacy chain to about 35 locations by the end of 2023.

4. Bad News, Challenges, or Points of Concern

• The gross margin declined due to market pressures from competitors selling low to medium-quality products at discounted prices.
• Patient count growth was only 18% in 2022, significantly lower than the company's revenue growth, indicating potential market saturation.
• Regulatory bottlenecks in Israel have historically limited the number of prescribing physicians, impacting patient access and market growth.
• The company faces challenges from financial instability among competitors, which may affect overall market pricing and dynamics.

5. Notable Q&A Insights

• Management acknowledged the competitive pressures due to struggling companies liquidating inventory at lower prices, impacting margins.
• There is cautious optimism regarding the prescription reform in Israel, which is expected to alleviate bottlenecks in patient access.
• The international expansion strategy is being approached carefully, with a focus on learning from past mistakes in other markets.
• Management indicated that while they are prepared for potential market growth, the timing of the prescription reform's implementation remains uncertain.
• Questions highlighted concerns about the sustainability of margins amid international expansion and the potential for continued price erosion in the Israeli market.

Overall, InterCure demonstrated strong financial performance in 2022, with significant growth and strategic expansions, but faces challenges related to market dynamics and regulatory hurdles.